View Document Preview and Link Document Date: 2012-06-25 09:55:50 Open Document File Size: 380,47 KB Share Result on Facebook
City Mississauga / / Company Antiviral Agent GlaxoSmithKline Inc. / GlaxoSmithKline Inc. / / Continent North America / Europe / / Country Japan / Canada / / Event FDA Phase / / IndustryTerm treatment of uncomplicated acute illness / treatment of influenza / alleviates the symptoms / treatment of patients with severe underlying airways disease / extemporaneous solution / inhalation device / / MedicalCondition respective influenza / abdominal pain / chronic illnesses / allergic reaction / laryngospasm / bronchospasm / annual influenza / influenza infection / arthralgia / uncomplicated acute illness / seizures / Stevens-Johnnson syndrome / dyspnea / shortness of breath / Immune/Infection Serious bacterial infections / Carcinogenesis / Influenza RELENZA / chronic obstructive pulmonary disease / hallucinations / severe chronic respiratory diseases / influenza A / mild/moderate asthma / ear / nose and throat infections nervous system dizziness / anaphylaxis / toxic epidermal necrolysis / severe renal insufficiency / fever / fatigue / obvious severe disease / injury / encephalopathy / urticaria / encephalitis / allergic reactions / suspected hypersensitivity / erythema multiforme / delirium / chronic pulmonary disease / airway disease / symptomatic influenza / influenza receiving RELENZA / respiratory disease / influenza / severe asthma / wheezing / serious bronchospasm / asthma / / MedicalTreatment vaccination / mechanical ventilation / / Organization AND ADMINISTRATION / National Advisory Committee on Immunization / DOSAGE AND ADMINISTRATION / / Position physician / General / / Product RELENZA / / ProvinceOrState Ontario / / Technology Geriatrics / pharmacokinetics / / SocialTag 
Microsoft Word - Relenza_PM _2012-05-29_.doc